Cashu
Ironwood Pharmaceuticals: Innovating Gastrointestinal Treatments for IBS and Chronic Constipation
about 1 month ago
Stocks
Health Care
irwd
Ironwood Pharmaceuticals
NASDAQ: IRWD
+0.88 (+26.26%)
4.255
USD
At close at Jan 02, 21:06 UTC
Overview
Loading chart...
Key Stats
Market Cap
547.40M
Dividend Yield
0.00%
P/E Ratio
19.17
EPS
0.00
Revenue
351.41M
Avg. Volume
1.53M
About
What does IRWD do?
Ironwood Pharmaceuticals, based in Boston, develops GI products including LINZESS for IBS-C and CIC, and is advancing treatments like apraglutide for rare GI diseases and IW-3300 for visceral pain conditions. The company, which went public in 2010, employs 267 people.
Join our newsletter to keep up to date with us!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.